Medullary Thyroid Cancer clinical trials

Explore recruiting medullary thyroid cancer clinical trials.

Recruiting medullary thyroid cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Medullary Thyroid Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients

Hungary, Poland, Romania, Croatia

Therapeutic use (Phase IV) EU CTIS Study details

Digoxin for the Reinduction or Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma.

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).

Spain, France, Germany, Italy, Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies

Spain, France, Germany, Italy, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

J2G-OX-Y001 - A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201)

Italy, France, Poland, Spain

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Denmark, France, Germany, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Medullary Thyroid Cancer trials by city

Medullary Thyroid Cancer in Toronto Medullary Thyroid Cancer in Vancouver Medullary Thyroid Cancer in Montreal Medullary Thyroid Cancer in Calgary Medullary Thyroid Cancer in Edmonton Medullary Thyroid Cancer in Ottawa Medullary Thyroid Cancer in Winnipeg Medullary Thyroid Cancer in Quebec City Medullary Thyroid Cancer in Hamilton Medullary Thyroid Cancer in Kitchener Medullary Thyroid Cancer in London Medullary Thyroid Cancer in Halifax Medullary Thyroid Cancer in New York Medullary Thyroid Cancer in Los Angeles Medullary Thyroid Cancer in Chicago Medullary Thyroid Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease